Physician profile
Bilal Khalid
NPI 1336371277
$471.05
in general payments reported to CMS, 2019-2025
13 companies · $157 in 2025
The $157 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $18.78 · 2022: $50.99 · 2023: $101 · 2024: $143 · 2025: $157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $401.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $401.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sirtex Medical INC | $143.44 | 2024 | Sir-Spheres Microspheres |
| Pfizer INC. | $48.66 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $47.95 | 2023 | |
| Gilead Sciences, INC. | $42.17 | 2025 | Trodelvy |
| Daiichi Sankyo INC. | $35.81 | 2022-2025 | Datroway |
| E.R. Squibb & Sons, L.L.C. | $26.13 | 2025 | |
| Sobi, INC | $24.99 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $21.69 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $18.78 | 2020 | |
| Array Biopharma INC | $16.43 | 2023 | Mektovi, Lorbrena, Braftovi |
| Glaxosmithkline, LLC. | $16.15 | 2025 | Jemperli, Zejula, Ojjaara |
| Pharmacyclics LLC, An Abbvie Company | $14.48 | 2023 | Imbruvica |
| Merck Sharp & Dohme LLC | $14.37 | 2025 | Lynparza, Keytruda Qlex, Keytruda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bilal Khalid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.